NCT03030105View on ClinicalTrials.gov

Study to Evaluate the Effects of BPN14770 on Scopolamine-induced Cognitive Impairment in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

May 31, 2017

Study Completion Date

June 30, 2017

Conditions
Alzheimer Disease
Interventions
DRUG

BPN14770

investigational drug

DRUG

BPN14770 placebo

placebo

DRUG

Donepezil

comparator

DRUG

Donepezil placebo

placebo

DRUG

Scopolamine 0.6 MG/ML

cognition impairment

DRUG

Scopolamine placebo

placebo

Trial Locations (1)

78209

ICON Early Phase Services, LLC, Austin

Sponsors
All Listed Sponsors
lead

Tetra Discovery Partners

INDUSTRY

NCT03030105 - Study to Evaluate the Effects of BPN14770 on Scopolamine-induced Cognitive Impairment in Healthy Volunteers | Biotech Hunter | Biotech Hunter